Gain Therapeutics (GANX) Short term Debt (2020 - 2025)
Historic Short term Debt for Gain Therapeutics (GANX) over the last 6 years, with Q3 2025 value amounting to $125545.0.
- Gain Therapeutics' Short term Debt rose 614.22% to $125545.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $125545.0, marking a year-over-year increase of 614.22%. This contributed to the annual value of $110177.0 for FY2024, which is 725.61% down from last year.
- Per Gain Therapeutics' latest filing, its Short term Debt stood at $125545.0 for Q3 2025, which was up 614.22% from $126108.0 recorded in Q2 2025.
- Gain Therapeutics' 5-year Short term Debt high stood at $126108.0 for Q2 2025, and its period low was $44287.0 during Q1 2021.
- In the last 5 years, Gain Therapeutics' Short term Debt had a median value of $109281.0 in 2023 and averaged $102318.0.
- Per our database at Business Quant, Gain Therapeutics' Short term Debt soared by 35887.92% in 2021 and then crashed by 725.61% in 2024.
- Gain Therapeutics' Short term Debt (Quarter) stood at $103826.0 in 2021, then rose by 4.15% to $108135.0 in 2022, then grew by 9.86% to $118797.0 in 2023, then fell by 7.26% to $110177.0 in 2024, then rose by 13.95% to $125545.0 in 2025.
- Its last three reported values are $125545.0 in Q3 2025, $126108.0 for Q2 2025, and $113121.0 during Q1 2025.